uploads/2018/06/tube-2338604_1280.jpg

Why Teligent Rose ~10.4% Yesterday

By

Updated

Teligent stock rises on news of FDA approval

On June 14, Teligent (TLGT) stock rose ~10.4% on the news of the FDA approval of its diflorasone diacetate ointment 0.05%. Investors were pleased with the news, and TLGT stock soared more than 10%. Teligent plans to launch the product in the third quarter of 2018.

Teligent is a New-Jersey-based specialty generic pharmaceutical firm that has a market capitalization of $193.2 million. It has a portfolio of topical generic products and four injectables products in the US. The approval of its diflorasone diacetate ointment 0.05% is the company’s fifth FDA approval in 2018.

Article continues below advertisement

As per IQVIA data, as of April 2018, the total addressable market for Teligent’s newly approved diflorasone diacetate ointment 0.05% is ~$14.1 million. Teligent stock was trading at its 52-week high of $9.54 on June 22, while its 52-week low of $2.43 was reported on March 15. The company closed at $3.61 on June 14. The stock is currently trading higher than its 50-day moving average of $2.98 and its 200-day moving average of $3.23.

Analysts’ recommendations for Teligent stock

As of June 15, Teligent stock has “buy” or “strong buy” recommendations from 50% of the six analysts included in a recent Reuters survey. The remaining 50% of analysts have a “hold” rating on Teligent. The stock doesn’t have any “sell” recommendations. The consensus target price for Teligent stock over the next 12 months is $5.3, which represents a return potential of ~46.8% for the next 12 months.

Be sure to check out all the data we’ve added to our quote pages. Now you can get a valuation snapshot, earnings and revenue estimates, and historical data, as well as dividend information. Take a look!

Advertisement

More From Market Realist